Jenburkt Pharmaceuticals Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: JENBURPH BSE: 524731
₹914.60
▼ -9.40 (-1.02%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
75/100
Strong
Valuation
57/100
Fairly Valued
Momentum
21/100
Bearish

QVM read Quality business Quality Strong, Valuation Fairly Valued, Momentum Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹404 Cr
PE (TTM)
12.3
Industry median 36.1 (152 companies)
Price to Book
2.0
PEG (TTM)
10.2
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
Data unavailable.
Free Cash Flow
₹13 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-24.46%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
8.77%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
9.08%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
5.85%
as of Sept. 30, 2025
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-0.04%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
4.11
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
90.38
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
22.31%
as of Sept. 30, 2025
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
19.43%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
25.83%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
15.07%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
23.16%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
17.29%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.00)
  • Yes Return on equity is 15% or more (17.3%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

1 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • No Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 2 met
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

0 of 4 met
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.0%
Low 911.2000 · High 944.0000
1W return
-3.9%
Low 911.1000 · High 974.9000
1M return
-13.0%
Low 911.1000 · High 1057.0000
52W return
Data unavailable.
Low 911.1000 · High 1073.9000
Lifetime High ₹1054.4000 (Aug. 19, 2026)
Lifetime Low ₹914.6000 (Sept. 30, 2026)

Full price history and technicals →

EMA & SMA

Bullish0
Bearish3
5D
931.4
10D
949.6
20D
976.3

Delivery and volume

Day avg. delivery
74.5%
Week avg. delivery
83.8%
Month avg. delivery
86.6%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

923.27
Pivot
First resistance935.33
Second resistance956.07
Third resistance968.13
First support902.53
Second support890.47
Third support869.73
Day RSI21.1
Day MFI18.1
Day MACD—
Day MACD signal—

Beta

1M0.86
3M0.78
1Y0.78
3Y0.78

Price change analysis

↓ -13.0%
Over 1 Month
LowHigh
911.101057.00
—
Over 3 Months
LowHigh
911.101073.90
—
Over 6 Months
LowHigh
911.101073.90
—
Over 1 Year
LowHigh
911.101073.90
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (June 30, 2026)
₹36 Cr
Net profit (June 30, 2026)
₹— Cr
Basic EPS (June 30, 2026)
₹13.3400

Ranks #107 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter46.62%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings decreased from 46.64% to 46.62% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
6 Jan 2023 JENBURKT PHARMACEUTICALS LTD Bulk Buy 47,037 649.9700 BSE
25 Aug 2020 ARIES STOCKTRADES PVT LTD A/C-PMS Bulk Sell 26,000 410.3900 BSE
8 Feb 2018 TRUPTI KETAN KARANI Bulk Sell 26,000 540.5000 BSE
8 Feb 2018 KETAN JAYANTILAL KARANI (HUF) Bulk Buy 26,000 540.5000 BSE
24 Oct 2017 RAJASTHAN GLOBAL SECURITIES PRIVATE LIMITED Bulk Buy 23,887 465.0000 BSE
5 Sep 2017 GIRIK WEALTH ADVISORS PRIVATE LIMITED-DEEP VALUE PMS Bulk Sell 30,794 433.2600 BSE
4 Nov 2016 Aries Stocktrades Pvt Ltd A/c-PMS Bulk Buy 23,591 566.6700 BSE
30 Jan 2015 DINERO WEALTH ADVISORS PRIVATE LIMITED Bulk Sell 30,000 347.0300 BSE
30 Jan 2015 KAUSHIK PARASKUMAR DAGA Bulk Buy 30,000 347.1200 BSE
30 Jul 2014 DINERO WEALTH ADVISORS PRIVATE LIMITED Bulk Buy 28,646 187.9500 BSE

All bulk and block deals →

Last 12 months ₹20.70 per share
Dividend yield 2.26%
Ex-dateSubjectPer share (₹)Record date
28 Aug 2026 Dividend - Rs 20.70 Per Share 20.7000 28 Aug 2026

Corporate Announcements

All 5 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
18 Sep 2026 Company Update Jenburkt Pharmaceuticals Ltd - 524731 - Announcement under Regulation 30 (LODR)-Change in Management
4 Sep 2026 AGM/EGM Jenburkt Pharmaceuticals Ltd - 524731 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
4 Sep 2026 AGM/EGM Jenburkt Pharmaceuticals Ltd - 524731 - Shareholder Meeting / Postal Ballot-Outcome of AGM
4 Sep 2026 Company Update Jenburkt Pharmaceuticals Ltd - 524731 - Announcement under Regulation 30 (LODR)-Change in Directorate
4 Sep 2026 Company Update Jenburkt Pharmaceuticals Ltd - 524731 - Proceedings Of The 41St Annual General Meeting Of The Company Held On Friday, 04Th September, 2026.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (22.3%)
  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (90.4x)

Weaknesses

  • Declining revenue YoY (-0.0%)

Opportunities

  • PE below 15 (12.3) relative to a typical growth business
  • RSI in oversold territory (21.1) -- a technical rebound zone

Threats

Data unavailable.

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Jenburkt Pharmaceuticals Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.